H.C. Wainwright raised the firm’s price target on Ardelyx (ARDX) to $18 from $10 and keeps a Buy rating on the shares. The firm is “encouraged” by the company having announced the successful new patent with expiration in November 2042.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARDX:
- Ardelyx: Strong Ibsrela Momentum, De-Risked CIC Upside, and Patent-Backed Undervaluation Support Buy Rating
- Ardelyx reports Q4 EPS 0c, consensus 1c
- Ardelyx Posts Strong 2025 Results, Projects 2026 Growth
- Ardelyx options imply 14.7% move in share price post-earnings
- ARDX Earnings Report this Week: Is It a Buy, Ahead of Earnings?